{
      "Rank": 673,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).",
            "CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time)."
      ],
      "ArmGroupInterventionName": [
            "Drug: Triamcinolone acetonide",
            "Biological: CELLISTEM-OA"
      ],
      "ArmGroupLabel": [
            "Group 1 (control-Triamcinolone acetonide)",
            "Group 2 (experimental- CELLISTEM-OA)"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04863183"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Symptomatic knee osteoarthritis is a serious public health problem in the world, it carries a high personal, social and economic impact. Currently, there are no drugs that modify the natural course of the disease. As analgesic therapy becomes insufficient, more invasive measures are applied, ultimately leading to arthroplasty.\n\nThe scientific community has joined efforts to develop new therapeutic approaches that allow the delay and regeneration of injured tissue in these patients. These include cell therapy with mesenchymal stem cells derived from different sources. Although most of the clinical studies carried out in different parts of the world with this therapy in patients with knee osteoarthritis have shown therapeutic benefit, it is necessary to develop clinical trials with high quality in our population.\n\nThe aim of this project is to evaluate the safety, tolerance and efficacy of Cellistem-OA (biological therapy based on mesenchymal stem cells derived from Wharton's jelly of umbilical cord) in patients with knee osteoarthritis in the Colombian population.\n\nInvestigators proposed to carry out an experimental (clinical trial), randomized, controlled and parallel with 30 participants with knee knee osteoarthritis of the medical complex Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle. The participants will be randomized into two groups: i) 15 patients who will receive a dose of 2 x 106 Cellistem-OA and ii) 15 patients who will receive an active comparator (acetonide of triamcinolone 10mg / mL), which will be administered by intra-articular injection in the superolateral aspect of the knee. The outcomes to be evaluated will be: (i) decrease in joint pain, (ii) increase in joint functionality, (iii) improvement in quality of life and (iv) improvement of articular cartilage. These parameters will be evaluated at weeks 1, 4, 8, 12, 24, 25, 28, 32, 36 and 52 post-treatments. Additionally, local and systemic adverse events will be recorded to establish whether or not there is an association between them and the intervention."
      ],
      "BriefTitle": [
            "Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis"
      ],
      "CentralContactEMail": [
            "martha.arango@foscal.com.co",
            "omaramado85@gmail.com"
      ],
      "CentralContactName": [
            "Martha L Arango, PhD",
            "Omar Amado, MD"
      ],
      "CentralContactPhone": [
            "(57) 3226816547",
            "(57)3108595352"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Cells for Cells"
      ],
      "CompletionDate": [
            "June 30, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Mesenchymal Stem Cells",
            "Knee Osteoarthritis",
            "Cell Therapy"
      ],
      "ConditionAncestorId": [
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216"
      ],
      "ConditionAncestorTerm": [
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteoarthritis",
            "Knee Osteoarthritis"
      ],
      "ConditionBrowseLeafId": [
            "M12078",
            "M21321",
            "M3628",
            "M9773",
            "M11249",
            "M14197",
            "M5475"
      ],
      "ConditionBrowseLeafName": [
            "Osteoarthritis",
            "Osteoarthritis, Knee",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010003",
            "D000020370"
      ],
      "ConditionMeshTerm": [
            "Osteoarthritis",
            "Osteoarthritis, Knee"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide)."
      ],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [
            "The Center for Advanced Therapies will send a pre-filled syringe with the 5 cc of solution without any difference in its external appearance, regardless of the content, according to the previously randomization."
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator"
      ],
      "DetailedDescription": [
            "Type of study Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide).\n\nStudy population Patients from the Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle who consult the trauma and rheumatology service by knee osteoarthritis. Patients who show interest in participating will be cited to an interview with the researchers where both the objectives and the research procedures will be explained.\n\nSample size The sample size considered are 30 participants distributed in two groups.\n\nGroup 1 (control) active comparator: triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc.\n\nGroup 2 (experimental): CELLISTEM-OA via intra-articular, doses of 2 x 106 cells in 5cc of saline solution.\n\nThe intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments using sterile technique, after cooling the skin with local ice."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients who / with:\n\nOsteoarthritis of the knee.\nKellgren II or III to knee radiography.\n30 to 75 years inclusive.\nPain scale greater than 40 over 100 mm.\nMRI with G I, II or III chondral knee injury with or without stable degenerative meniscal injury.\nStable knee.\nExamination of the rest of the normal limb.\nWillingness to participate in the study for 1 year.\nAbility to understand and willingness to sign the informed consent.\n\nExclusion Criteria:\n\nPatients who / with:\n\nSymptomatic contralateral knee osteoarthritis.\nSignificant knee trauma in the preceding 3 months.\nWound or skin lesion in the knee studied.\nAnatomical valgus greater than 10\u00ba.\nAnatomical varus greater than 5\u00ba.\nClinically significant joint effusion.\nEdema greater than 20% of the surface of the plateau or condyle in NMR.\nPreviously known alterations in the hip and / or spine.\nPredominant patellofemoral pathology (radiographs with IWANO II osteoarthritis or more).\nAny type of inflammatory arthritis.\nHistory of active infections including HIV, HBV and HCV.\nResults of laboratory tests (hemogram and CRP) outside the normal ranges.\nPresence of fever on day -1 or day 0.\nUse of oral corticosteroids.\nUse of anticoagulants.\nImmunosuppression, uncontrolled diabetes mellitus, hyperthyroidism, psychiatric illnesses\nActive neoplasia or during the preceding 5 years.\nPregnancy or breastfeeding (b-Hcg positive).\nUse of drugs or alcoholism.\nIA injections or knee surgeries in the last 180 days.\nBMI> 35.\nAny type of metallic implant susceptible to displacement with MRI.\nUse of pacemakers.\nHistory of severe allergy or anaphylactic shock.\nSignificant alterations in the evaluation of the initial laboratory tests.\nAny factor that, in the opinion of the investigator, may affect the adequate follow-up of the patient during the study"
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000005938",
            "D000006728",
            "D000006730",
            "D000045505",
            "D000007166",
            "D000007155",
            "D000004791",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormones, Hormone Substitutes, and Hormone Antagonists",
            "Physiological Effects of Drugs",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "Group 2 (experimental- CELLISTEM-OA)",
            "Group 1 (control-Triamcinolone acetonide)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All",
            "Infl"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals",
            "Anti-Inflammatory Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Pulse",
            "Periodontal",
            "Periodontal",
            "Periodontal"
      ],
      "InterventionBrowseLeafId": [
            "M21013",
            "M16126",
            "M16127",
            "M237968",
            "M209570",
            "M3369",
            "M8199",
            "M8941",
            "M8940",
            "M9364",
            "M9353"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions",
            "Triamcinolone",
            "Triamcinolone Acetonide",
            "Triamcinolone hexacetonide",
            "Triamcinolone diacetate",
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormone Antagonists",
            "Immunosuppressive Agents",
            "Immunologic Factors"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.",
            "The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice."
      ],
      "InterventionMeshId": [
            "D000014221",
            "D000014222",
            "C000005900",
            "C000030262"
      ],
      "InterventionMeshTerm": [
            "Triamcinolone",
            "Triamcinolone Acetonide",
            "Triamcinolone hexacetonide",
            "Triamcinolone diacetate"
      ],
      "InterventionName": [
            "CELLISTEM-OA",
            "Triamcinolone acetonide"
      ],
      "InterventionOtherName": [
            "Mesenchymal stem cells",
            "Kenacort-A"
      ],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "April 28, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 23, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [],
      "LocationFacility": [],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "30 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Cell Therapy for Patients With Symptomatic Knee Osteoarthritis: Phase I / II, Controlled, Randomized and Double-blind Clinical Trial"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle"
      ],
      "OrgStudyId": [
            "OA-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle"
      ],
      "OverallOfficialName": [
            "Martha L Arango, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Not yet recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Pain will be measured through visual analog scale (VAS).",
            "Joint functionality will be measured through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).",
            "Quality of life will be measured through the Short Form 36 Health Survey Questionnaire (SF-36).",
            "The improvement of articular cartilage will be evaluated by nuclear magnetic resonance (NMR)."
      ],
      "PrimaryOutcomeMeasure": [
            "Decrease in joint pain",
            "Increased joint functionality",
            "Improvement in the quality of life",
            "Imaging improvement of articular cartilage"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Fundaci\u00f3n Oftalmol\u00f3gica de Santander Cl\u00ednica Carlos Ardila Lulle"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Martha Ligia Arango Rodr\u00edguez"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Director Technical and Scientific Centro de Terapias Avanzadas Fundaci\u00f3n Ofalmol\u00f3gica de Santander"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [],
      "SecondaryOutcomeTimeFrame": [],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 1, 2021"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "April 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 28, 2021"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "April 20, 2021"
      ],
      "StudyFirstSubmitQCDate": [
            "April 23, 2021"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}